- Home
- ANNX vs EBS Comparison
ANNX vs EBS Comparison
Compare ANNX & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- EBS
- Stock Information
- Founded
- ANNX 2011
- EBS 1998
- Country
- ANNX United States
- EBS United States
- Employees
- ANNX N/A
- EBS N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- ANNX Health Care
- EBS Health Care
- Exchange
- ANNX Nasdaq
- EBS Nasdaq
- Market Cap
- ANNX 553.2M
- EBS 518.0M
- IPO Year
- ANNX 2020
- EBS 2006
- Fundamental
- Price
- ANNX $4.20
- EBS $9.87
- Analyst Decision
- ANNX Strong Buy
- EBS Strong Buy
- Analyst Count
- ANNX 7
- EBS 3
- Target Price
- ANNX $15.80
- EBS $14.33
- AVG Volume (30 Days)
- ANNX 1.5M
- EBS 1.1M
- Earning Date
- ANNX 11-14-2024
- EBS 03-04-2025
- Dividend Yield
- ANNX N/A
- EBS N/A
- EPS Growth
- ANNX N/A
- EBS N/A
- EPS
- ANNX N/A
- EBS N/A
- Revenue
- ANNX N/A
- EBS $1,125,500,000.00
- Revenue This Year
- ANNX N/A
- EBS $6.26
- Revenue Next Year
- ANNX N/A
- EBS $2.42
- P/E Ratio
- ANNX N/A
- EBS N/A
- Revenue Growth
- ANNX N/A
- EBS 2.05
- 52 Week Low
- ANNX $3.86
- EBS $1.42
- 52 Week High
- ANNX $8.40
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- ANNX 31.21
- EBS 56.65
- Support Level
- ANNX $4.53
- EBS $9.20
- Resistance Level
- ANNX $4.99
- EBS $10.11
- Average True Range (ATR)
- ANNX 0.31
- EBS 0.67
- MACD
- ANNX -0.08
- EBS 0.04
- Stochastic Oscillator
- ANNX 14.07
- EBS 71.64
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.